By Fineline Cube 
China-based Kexing Pharmaceutical (SHA: 688136) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its GB18 in cancer cachexia. This follows the drug’s previous clearance for clinical trials in the US.
GB18 Mechanism and Innovation
GB18 is a novel drug targeting growth differentiation factor-15 (GDF-15). It features a unique FC fusion nanobody structure design, enhancing the drug’s stability and bioavailability while significantly improving its ability to inhibit signal pathway transmission.
Preclinical Results
Preclinical studies demonstrated significant differentiated advantages of GB18. The drug reversed weight loss in animal models, improved muscle and fat mass, and enhanced exercise ability. Administered via subcutaneous injection every 3-4 weeks, GB18 is designed to reduce the medication burden on patients and improve compliance.-Fineline Info & Tech